Literature DB >> 14593747

Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents.

Khandan Keyomarsi1, Arthur B Pardee.   

Abstract

A major problem of cancer therapy is to not kill the normal cells essential for life while killing the great majority of cancer cells. Subtle differences that arise during progression of cancer can provide novel therapies, such as targeting normal cells for protection against chemotoxicity. The increasing understanding gained by applying cellular and molecular biological techniques including expression genetics to detect molecular differences is revealing potential targets, related to cell proliferation, apoptosis, and differentiation. The quantitative differences of gene or enzyme expression between normal and tumor cells have provided the basis for drug discovery that can either reversibly target the normal cells or differentially target the tumor cells. Such differences also emphasize the need for the application of multiple drugs, with different modes of action.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14593747

Source DB:  PubMed          Journal:  Prog Cell Cycle Res        ISSN: 1087-2957


  8 in total

1.  A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells.

Authors:  Aruna S Jaiswal; Sanjeev Banerjee; Harekrushna Panda; Charles D Bulkin; Tadahide Izumi; Fazlul H Sarkar; David A Ostrov; Satya Narayan
Journal:  Mol Cancer Res       Date:  2009-12-08       Impact factor: 5.852

2.  Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index.

Authors:  Changhan Lee; Fernando M Safdie; Lizzia Raffaghello; Min Wei; Federica Madia; Edoardo Parrella; David Hwang; Pinchas Cohen; Giovanna Bianchi; Valter D Longo
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

Review 3.  Nutrition in Cancer: Evidence and Equality.

Authors:  Christopher P Haskins; Colin E Champ; Robert Miller; Melissa A L Vyfhuis
Journal:  Adv Radiat Oncol       Date:  2020-05-24

4.  Merging high-quality biochemical fractionation with a refined flow cytometry approach to monitor nucleocytoplasmic protein expression throughout the unperturbed mammalian cell cycle.

Authors:  Margit Rosner; Katharina Schipany; Markus Hengstschläger
Journal:  Nat Protoc       Date:  2013-02-28       Impact factor: 13.491

5.  Amino acid Asp181 of 5'-flap endonuclease 1 is a useful target for chemotherapeutic development.

Authors:  Harekrushna Panda; Aruna S Jaiswal; Patrick E Corsino; Melissa L Armas; Brian K Law; Satya Narayan
Journal:  Biochemistry       Date:  2009-10-27       Impact factor: 3.162

6.  NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.

Authors:  Debajit K Biswas; Qian Shi; Shanon Baily; Ian Strickland; Sankar Ghosh; Arthur B Pardee; J Dirk Iglehart
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-25       Impact factor: 11.205

7.  Perturbation of interaction networks for application to cancer therapy.

Authors:  Adrian P Quayle; Asim S Siddiqui; Steven J M Jones
Journal:  Cancer Inform       Date:  2007-04-01

8.  Suppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopecia.

Authors:  Zeina Nasr; Lukas E Dow; Marilene Paquet; Jennifer Chu; Kontham Ravindar; Ragam Somaiah; Pierre Deslongchamps; John A Porco; Scott W Lowe; Jerry Pelletier
Journal:  BMC Pharmacol Toxicol       Date:  2013-11-13       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.